March 3rd, 2021 | by BTP Admin
$231.8 million U.S. funding awarded to Ellume COVID-19 Home Test that integrates AnteoBind™ for superior sensitivity
Brisbane, AUS, February 15, 2021 — AnteoTech’s long-term customer Ellume, producer of next-generation digitally enabled diagnostic solutions, has secured a $231.8 million agreement with the U.S. Government to support accelerated manufacture of its COVID-19 home test. The test makes use of AnteoTech’s unique AnteoBind™ technology to support significantly improved sensitivity, and is the first rapid self-test for SARS-CoV-2 detection authorized by the United States Food and Drug Administration (FDA) for use without a prescription. Through the patented AnteoBind technology and the expertise and know-how delivered via its Contract Services in assay development and bioconjugation, AnteoTech continues to address the pressing challenges of the point-of-care diagnostics, biopharmaceutical and vaccine development markets.
With the help of AnteoTech’s AnteoBind technology, the Ellume COVID-19 Home Test provides accurate results in 15 minutes or less, detecting SARS-CoV-2 in both symptomatic and asymptomatic individuals. Ellume’s offering is the first test which utilizes AnteoBind to receive FDA Emergency Use Authorization (EUA).
Pictured: The Ellume COVID-19 Home Test.
“With the Ellume test receiving FDA authorization and subsequent significant financial backing from the U.S. Government, this is further evidence of the immense value the AnteoBind technology continues to bring to the life sciences industry for life-changing solutions,” said Derek Thomson, Chief Executive Officer of AnteoTech. “The capabilities of high-sensitivity diagnostics, such as Ellume’s COVID-19 Home Test, will ultimately enable rapid and reliable screening to minimize community spread, relieve burden on healthcare systems and facilitate the reopening of economies.”
AnteoBind is a nano-sized molecular glue used to facilitate simpler, faster and more reliable bioconjugation. The improved conjugation process increases the performance for diagnostic assays, and enables superior quality control, candidate screening and efficacy-measurement processes in biopharmaceutical and vaccine development. The Ellume COVID-19 Home Test is an example of how AnteoBind technology can aid in delivering conjugation stability, unmatched sensitivity and batch-to-batch reproducibility – all while being manufactured at scale.
Dr. Sean Parsons, Chief Executive Officer of Ellume, said “Our recent Emergency Use Authorization was a key milestone in our mission to make a significant contribution to global health. AnteoTech’s AnteoBind has greatly assisted us in the development of a highly sensitive test that is vital for an effective COVID-19 mitigation strategy. We look forward to our continued partnership with AnteoTech as we deliver accurate diagnostic solutions to the market.”
AnteoTech’s AnteoBind can be purchased directly as an AnteoBind-based ready-to-use kit to streamline and improve the conjugation process, or is available through AnteoTech’s Assay Development Services. The Assay Development Services are focused on the application of AnteoBind, and draw on the AnteoTech team’s extensive biomedical research and assay development experience, particularly in difficult conjugation assay design and quantitative assay design.
For more information on AnteoTech’s AnteoBind technology and Contract Services, please visit: https://www.anteotech.com/life-science/anteobind/.
About AnteoTech Ltd.
AnteoTech is a surface chemistry company with Intellectual Property in its core technology product groups AnteoBindTM, AnteoCoatTM, and AnteoReleaseTM. The company is committed to creating shareholder value by identifying and solving critical global industry problems through unique value-add solutions. AnteoTech serves companies in the life sciences, diagnostics and energy markets.
For more information:
+61 7 3219 0085
Media enquires: Janice Foley
May 27th, 2020 | by BTP Admin
Australia’s identity in the new COVID-era has been likened to the early 1980s, with an emerging manufacturing sector, home grown innovation, and the rise of the suburban office park.
As Back to the Future debuted in cinemas in 1985 with a fresh-faced Michael J Fox, the 33 ha Brisbane Technology Park was making its own debut in Eight Mile Plans, 15km south-east of the Brisbane CBD.
It is a concept that has stood the test of time, with its open outdoor spaces, low density, surplus parking, and accessible urban setting showing strong appeal to businesses planning a future in the new COVID world.
Graystone Group, which has overseen the growth of the BTP precinct since 2001, says the open format of suburban office parks offsets many challenges being experienced by their CBD counterparts.
Graystone’s Director of Developments & Property Management, Kirsty Heymink, said the precinct is home to more than 200 businesses and expected the number to grow as COVID restrictions begin to ease.
“There is still a level of positivity in the market, despite the challenges we’ve all faced,” she said.
“In recent weeks we have started fielding new enquiries from small to medium-sized businesses who are looking to spread their workforce across larger, more flexible spaces. The green shoots are emerging, albeit cautiously, and we’re in an excellent position to nurture them.”
Ms Heymink said Brisbane Technology Park has evolved sustainably over time to deliver a leading master planned precinct of premium A-grade equivalent office buildings, serviced office suits, a boutique hotel, casual dining, and expansive outdoor amenity.
“Business parks have the luxury of space and master planning, so larger floor plates are commonplace and replace the need for excessive building heights,” Ms Heymink said.
“Buildings range between one and three levels and feature secure stair access, creating less reliance on lifts. The office park model also enables businesses to spread their workforce over multiple locations to mitigate risk, with flexible lease terms.
“This approach enables companies to keep some degree of separation between team members without having to sacrifice productivity and collaboration, while maintaining the benefits of social interaction, idea sharing, and a supportive workplace culture.
“There is also a reduced dependence on public transport, with ample free street parking and low-cost onsite parking. These are an attractive proposition for companies grappling with how their workforce can function safely, and productively, until a vaccine for COVID is available.”
Ms Heymink said COVID has proven to many businesses that working from home, while achievable in the short term, brings its own challenges of isolation, poor network infrastructure, and lessened productivity.
“While there is still an important and undeniable place for offices in our future, they may not be as CBD-centric as they once were,” she said.
In addition to Brisbane Technology Park, Graystone Group also manages BTP Westlink Green in Darra, and BTP Northshore Hamilton.
Established in 1985, Graystone Group manages commercial office assets across Brisbane Technology Park, Westlink Green and Northshore Hamilton. Its core operations include precinct development, construction, project management, property management, and investment. The Queensland Government appointed Graystone as Development Manager for the 33ha Brisbane Technology Park precinct in 2001.
If you are looking to relocate your business and are interested to know more about BTP please contact our friendly and knowledgeable leasing team on 3368 9099, or alternatively have a look at our current listings.